

# **Synonym**

Spike,S protein,Spike glycoprotein,S glycoprotein

#### **Source**

SARS-CoV-2 Spike Trimer, His Tag (BA.4.6/Omicron) (SPN-C522m) is expressed from human 293 cells (HEK293). It contains AA Val 16 - Pro 1213 (Accession # QHD43416.1 (T19I, LPP24-26del, A27S, HV69-70del, G142D, V213G, G339D, R346T, S371F, S373P, S375F, T376A, D405N, R408S, K417N, N440K, L452R, S477N, T478K, E484A, F486V, Q498R, N501Y, Y505H, D614G, H655Y, N658S, N679K, P681H, N764K, D796Y, Q954H, N969K, R683A, R685A, F817P, A892P, A899P, A942P, K986P, V987P)). The spike mutations are identified on the SARS-CoV-2 Omicron variant (Pango lineage: BA.4.6). The recombinant protein is expressed from human 293 cells (HEK293) with T4 fibritin trimerization motif and a polyhistidine tag at the C-terminus. Proline substitutions (F817P, A892P, A899P, A942P, K986P, V987P) and alanine substitutions (R683A and R685A) are introduced to stabilize the trimeric prefusion state of SARS-CoV-2 S protein and abolish the furin cleavage site, respectively.

Predicted N-terminus: Val 16

# **Molecular Characterization**

This protein carries a polyhistidine tag at the C-terminus

The protein has a calculated MW of 137.7 kDa. The protein migrates as 160-200 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

# Endotoxin

Less than 1.0 EU per µg by the LAL method.

# **Purity**

>95% as determined by SDS-PAGE.

>90% as determined by SEC-MALS.

#### **Formulation**

Lyophilized from 0.22 µm filtered solution in PBS with trehalose as protectant.

Contact us for customized product form or formulation.

# Reconstitution

Please see Certificate of Analysis for specific instructions.

For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

# **Storage**


For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:

- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.


# **SDS-PAGE**



SARS-CoV-2 Spike Trimer, His Tag (BA.4.6/Omicron) on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.

# **Bioactivity-ELISA**


# SEC-MALS




The purity of SARS-CoV-2 Spike Trimer, His Tag (BA.4.6/Omicron) (Cat. No. SPN-C522m) is more than 90% and the molecular weight of this protein is around 520-565 kDa verified by SEC-MALS.

Report






Immobilized Human ACE2, Fc Tag (Cat. No. AC2-H5257) at 5  $\mu$ g/mL (100  $\mu$ L/well) can bind SARS-CoV-2 Spike Trimer, His Tag (BA.4.6/Omicron) (Cat. No. SPN-C522m) with a linear range of 0.2-10 ng/mL (QC tested).



Anti-SARS-CoV-2 Spike RBD Broadly Neutralizing Antibody, Human IgG1 Conc. (ng/mL)

Immobilized SARS-CoV-2 Spike Trimer, His Tag (BA.4.6/Omicron) (Cat. No. SPN-C522m) at 2  $\mu$ g/mL (100  $\mu$ L/well) can bind Anti-SARS-CoV-2 Spike RBD Broadly Neutralizing Antibody, Human IgG1 (Cat. No. SPD-M265) with a linear range of 0.2-2 ng/mL (Routinely tested).



Anti-SARS-CoV-2 Spike RBD Antibody, Chimeric mAb, Human IgG1 Conc. (ng/mL)

Immobilized SARS-CoV-2 Spike Trimer, His Tag (BA.4.6/Omicron) (Cat. No. SPN-C522m) at 2  $\mu$ g/mL (100  $\mu$ L/well) can bind Anti-SARS-CoV-2 Spike RBD Antibody, Chimeric mAb, Human IgG1 (Cat. No. S1N-M130) with a linear range of 0.1-1 ng/mL (Routinely tested).

# **Background**

It's been reported that SARS-CoV-2 can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion. The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity.

# **Clinical and Translational Updates**

Please contact us via <u>TechSupport@acrobiosystems.com</u> if you have any question on this product.